Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin.
10.3760/cma.j.issn.0253-2727.2023.01.018
- Author:
Ming Ci CAI
1
,
2
;
Peng Peng XU
1
,
2
;
Wei Li ZHAO
1
,
2
Author Information
1. National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics
2. Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200025, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Brentuximab Vedotin;
Ki-1 Antigen;
Antineoplastic Agents;
Immunoconjugates/therapeutic use*;
Lymphoma/drug therapy*
- From:
Chinese Journal of Hematology
2023;44(1):81-86
- CountryChina
- Language:Chinese
